Exciting new developments at Quotient Bioresearch with announcement of deal with GE

Exciting new developments at Quotient Bioresearch with announcement of deal with GE

Quotient Bioresearch acquires radiochemical custom synthesis operations from GE Healthcare. Acquired business to provide Quotient-Amersham Radiochemicals branded products and services. Major investment in new radiochemicals facility to be located in Cardiff, Wales.

Quotient Bioresearch: High-throughput biomarker analysis delivers maximum information from each sample

Quotient Bioresearch highlights new approach at World Congress

At the recent Biomarker World Congress 2009, held in Philadelphia, USA, 27 – 29 May, Dr Craig Stovold, Senior Project Manager-Bioanalytical Sciences, Quotient Bioresearch, reported on how the company’s multiplexed assays are delivering more data, on a greater number of analytes and in a shorter time – getting as much information as possible from each sample.

QUOTIENT BIORESEARCH ACQUIRES EDINBURGH CLINICAL RESEARCH FACILITY

CAMBRIDGESHIRE, UK, 18th May 2009 – Quotient Bioresearch Limited
(“Quotient”), a leading provider of drug development services, today announces that it has acquired Charles River Laboratories’ (Charles River) Edinburgh clinical research facility. This represents the sixth acquisition in approximately three years for Quotient. The Charles River facility, formerly Inveresk Clinical Research, will combine with Pharmaceutical Profiles, acquired by Quotient in December 2008, to form a new
strategic business unit within Quotient - Quotient Clinical.